Edwards Lifesciences Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax increased by 14.3% to $1.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 59.0%, from $3.90M to $1.60M. This increase may warrant attention — for this metric, lower values are generally preferred.
Higher unrealized losses often signal rising interest rates or credit deterioration in the investment portfolio.
This metric tracks the total gross unrealized losses on debt securities classified as available-for-sale. It represents...
Unrealized losses are a key focus for investors during periods of rising interest rates, as they impact the bank's book value.
other_available_for_sale_debt_securities_accumulated_gro_6005e2| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.20M | $2.10M | $11.90M | $52.00M | $67.60M | $78.00M | $68.10M | $55.10M | $49.20M | $38.70M | $27.50M | $18.00M | $12.80M | $6.90M | $5.30M | $3.90M | $2.80M | $2.00M | $1.40M | $1.60M |
| QoQ Change | — | +75.0% | +466.7% | +337.0% | +30.0% | +15.4% | -12.7% | -19.1% | -10.7% | -21.3% | -28.9% | -34.5% | -28.9% | -46.1% | -23.2% | -26.4% | -28.2% | -28.6% | -30.0% | +14.3% |
| YoY Change | — | — | — | — | >999% | >999% | +472.3% | +6.0% | -27.2% | -50.4% | -59.6% | -67.3% | -74.0% | -82.2% | -80.7% | -78.3% | -78.1% | -71.0% | -73.6% | -59.0% |